David A. Siegel Amylyx Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 241,400 shares of AMLX stock, worth $873,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
241,400
Previous 309,500
22.0%
Holding current value
$873,868
Previous $1 Million
9.18%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AMLX
# of Institutions
142Shares Held
45.3MCall Options Held
235KPut Options Held
498K-
Perceptive Advisors LLC New York, NY6.77MShares$24.5 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$16.8 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$9.75 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$9.66 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$8.78 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $212M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...